Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Medicines Company
The primary objective was to establish the safety of clevidipine in the treatment of perioperative hypertension, as assessed by comparing the incidences of death, stroke, MI and renal dysfunction in the clevidipine and sodium nitroprusside treatment groups from the initiation of study drug infusion through postoperative Day 30. Secondary objectives were to evaluate the efficacy of study drug, assessed by the blood pressure (BP) lowering effect and additional safety variables.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provide written informed consent before initiation of any study related procedures.
Be at least 18 years of age
Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery
Determined to be hypertensive perioperatively as determined by the investigator
You may not be if
Women of child-bearing potential (unless they have a negative pregnancy test)
Recent cerebrovascular accident (within 3 months before randomization)
Known intolerance to calcium channel blockers
Known or suspected hypersensitivity to sodium nitroprusside
Allergy to soybean oil or egg lecithin (components of the lipid vehicle)
Pre-existing permanent ventricular pacing
Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial
Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study